IRA S. WOLLNER
Henry Ford Hospital · 43 works · 4,483 citations · h-index 16
Top works
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- Effects of hepatic arterial yttrium 90 glass microspheres in dogs
- Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Vascular endothelial growth factor in the management of hepatocellular carcinoma
- Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs.
- Squamous cell carcinoma of the buccal mucosa with metastases to the pericardial cavity, lung and thyroid
- Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
- Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies
- Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude mice.
- Adenocarcinoma of the Head of the Pancreas: Effects of Surgical and Nonsurgical Therapy on Survival—A Ten-Year Experience
- Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists
- Phase II Study of Hepatic Arterial Degradable Starch Microspheres and Mitomycin
- Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
- Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma
- A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
- Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
- A dog model using an implanted system for protracted hepatic arterial chemotherapy
- Combination Chemo-radiation Therapy for Jaundice Due to Focal Malignant Obstruction of the Major Bile Ducts